Candel Therapeutics
CADL
20 hedge funds and large institutions have $4.86M invested in Candel Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 20 → 20 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.39% less ownership
Funds ownership: 18.57% → 18.18% (-0.39%)
28% less capital invested
Capital invested by funds: $6.77M → $4.86M (-$1.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$37.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$445 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$165 |
| 5 |
JP Morgan Chase
New York
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$149K |
| 2 |
Renaissance Technologies
New York
|
-$16K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.6K |
| 4 |
BWM
Baystate Wealth Management
Boston,
Massachusetts
|
-$3.73K |
| 5 |
BlackRock
New York
|
-$2.28K |
CADL Hedge Fund Activity: Q3 2023 in Review
20 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q3 2023, worth a combined $4.86M — down 28% from $6.77M a quarter earlier.
Fund positioning in CADL was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $37.2K. The largest seller was Citigroup, exiting entirely with an estimated $149K sold.
- 20 institutional investors held Candel Therapeutics (CADL) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $4.86M of Candel Therapeutics stock for Q3 2023, down 28% quarter-over-quarter.
- 2 funds opened new Candel Therapeutics positions in Q3 2023 and 2 closed out, a net change of 0 holders.
- The largest Candel Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $37.2K added.
- The largest Candel Therapeutics seller in Q3 2023 was Citigroup, an estimated $149K sold.
Based on aggregated 13F filings for Q3 2023.